Table 1.
Comparison of patient and tumor characteristics in the subgroups with and without microvascular invasion.
| No vascular invasion (n = 222) | Vascular invasion (n = 114) | p = | |
|---|---|---|---|
| Male | 174 (78%) | 100 (88%) | 0.037 |
|
| |||
| Mean age at LT [years] | 57 ± 1 | 56 ± 1 | 0.840 |
|
| |||
| Era of transplantation | 0.011 | ||
| (i) Before 1997 | 47 (21%) | 29 (25%) | |
| (ii) 1997–2003 | 58 (26%) | 44 (39%) | |
| (iii) 2004 to 2008 | 117 (53%) | 41 (36%) | |
|
| |||
| Underlying liver disease | 0.777 | ||
| (i) Alcohol | 57 (26%) | 34 (30%) | |
| (ii) HCV | 81 (37%) | 39 (34%) | |
| (iii) HBV | 36 (16%) | 19 (17%) | |
| (iv) Cryptogenic | 35 (16%) | 14 (12%) | |
| (v) Others | 13 (6%) | 8 (7%) | |
|
| |||
| Recipient blood group | 0.958 | ||
| (i) 0 | 58 (29%) | 33 (30%) | |
| (ii) A | 110 (55%) | 58 (52%) | |
| (iii) B | 22 (11%) | 14 (13%) | |
|
| |||
| Mean waiting time | 142 ± 13 | 124 ± 15 | 0.120 |
|
| |||
| Child Pugh stadium | 0.809 | ||
| (i) A | 95 (43%) | 44 (39%) | |
| (ii) B | 97 (44%) | 51 (45%) | |
| (iii) C | 30 (14%) | 19 (17%) | |
|
| |||
| TACE before LT | 60 (27%) | 29 (25%) | 0.888 |
|
| |||
| Previous liver resection | 23 (10%) | 6 (5%) | 0.163 |
|
| |||
| Piggy back | 71 (32%) | 27 (24%) | 0.263 |
|
| |||
| Tumor biopsy | 0.553 | ||
| (i) Yes | 46 (21%) | 29 (25%) | |
| (ii) No | 147 (66%) | 69 (61%) | |
| (iii) Unknown | 29 (13%) | 16 (14%) | |
|
| |||
| No blood transfusions (24 h) | 28 (15%) | 15 (15%) | 0.561 |
|
| |||
| Mechanical ventilation >24 h | 11 (6%) | 9 (9%) | 0.255 |
|
| |||
| Haemodialysis after LT | 27 (12%) | 16 (14%) | 0.496 |
|
| |||
| Number of tumor nodules | 0.055 | ||
| (i) ≤3 | 195 (88%) | 91 (80%) | |
| (ii) >3 | 27 (12%) | 23 (20%) | |
|
| |||
| Maximum tumor diameter | <0.001 | ||
| (i) ≤5 cm | 194 (87%) | 79 (69%) | |
| (ii) >5 cm | 28 (13%) | 35 (31%) | |
|
| |||
| Mean max. diameter [cm] | 3.1 ± 0.2 | 4.7 ± 0.3 | 0.005 |
|
| |||
| Mean AFP [μg/l] | 583 ± 241 | 3120 ± 1350 | 0.005 |
|
| |||
| AFP category | 0.023 | ||
| (i) <20 | 115 (52%) | 46 (40%) | |
| (ii) 21–100 | 45 (20%) | 15 (13%) | |
| (iii) 101–1000 | 33 (15%) | 25 (22%) | |
| (iv) >1000 | 12 (5%) | 14 (12%) | |
| (v) Not determined | 17 (8%) | 14 (12%) | |
|
| |||
| Tumor grading | <0.001 | ||
| (i) G1 | 54 (24%) | 7 (6%) | |
| (ii) G2 | 121 (55%) | 60 (53%) | |
| (iii) G3 | 27 (12%) | 13 (40%) | |
| (iv) Gx | 20 (9%) | 1 (1%) | |